{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:43:09Z","timestamp":1793727789426,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.diabet.2025.101613","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T05:08:45Z","timestamp":1737090525000},"page":"101613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-9562","authenticated-orcid":false,"given":"Mahmoud","family":"Nassar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Abosheaishaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Dandona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Ghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101613_bib0001","doi-asserted-by":"crossref","first-page":"e13547","DOI":"10.1111\/1753-0407.13547","article-title":"Impact of treatment with GLP-1RAs on suicide attempts in adults persons with type 2 diabetes: a retrospective comparative effectiveness study based on a global TriNetX health research database","volume":"16","author":"Nassar","year":"2024","journal-title":"J Diabetes"},{"key":"10.1016\/j.diabet.2025.101613_bib0002","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/dom.12025","article-title":"Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature","volume":"15","author":"Balena","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0003","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2337\/dc08-1755","article-title":"Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study","volume":"32","author":"Noel","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101613_bib0004","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.15077","article-title":"New insights into the treatment of obesity","volume":"25","author":"Bluher","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0005","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0006","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/dom.13924","article-title":"Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials","volume":"22","author":"Abd El Aziz","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0007","first-page":"124","article-title":"Acute pancreatitis due to different semaglutide regimens: an updated meta-analysis","volume":"71","author":"Masson","year":"2024","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"10.1016\/j.diabet.2025.101613_bib0008","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0009","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2337\/db13-1268","article-title":"Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies","volume":"63","author":"Chadwick","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101613_bib0010","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1185\/03007990902820519","article-title":"Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide","volume":"25","author":"Dore","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabet.2025.101613_bib0011","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1463-1326.2011.01376.x","article-title":"A cohort study of acute pancreatitis in relation to exenatide use","volume":"13","author":"Dore","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0012","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2337\/dc16-2747","article-title":"Investigators LT: amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER Randomized Trial","volume":"40","author":"Steinberg","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2025.101613_bib0013","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/db09-0626","article-title":"Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice","volume":"58","author":"Koehler","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101613_bib0014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/labinvest.2013.133","article-title":"PSCs and GLP-1R: occurrence in normal pancreas, acute\/chronic pancreatitis and effect of their activation by a GLP-1R agonist","volume":"94","author":"Nakamura","year":"2014","journal-title":"Lab Invest"},{"key":"10.1016\/j.diabet.2025.101613_bib0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","article-title":"Pancreatic safety of incretin-based drugs- FDA and EMA assessment","volume":"370","author":"Egan","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101613_bib0016","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","article-title":"Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model","volume":"61","author":"Gier","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2025.101613_bib0017","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s10620-017-4621-z","article-title":"Validation of demographics, etiology, and risk factors for chronic pancreatitis in the USA: a report of the North american pancreas study (NAPS) group","volume":"62","author":"Conwell","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.diabet.2025.101613_bib0018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2188\/jea.JE20140152","article-title":"Pyogenic liver abscess correlates with increased risk of acute pancreatitis: a population-based cohort study","volume":"25","author":"Lai","year":"2015","journal-title":"J Epidemiol"},{"key":"10.1016\/j.diabet.2025.101613_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5009\/gnl.2011.5.3.335","article-title":"Influence of obesity on the severity and clinical outcome of acute pancreatitis","volume":"5","author":"Shin","year":"2011","journal-title":"Gut Liver"},{"key":"10.1016\/j.diabet.2025.101613_bib0020","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cgh.2007.06.002","article-title":"Risk of pancreatitis in 14,000 individuals with celiac disease","volume":"5","author":"Ludvigsson","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.diabet.2025.101613_bib0021","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1210\/jc.2003-032103","article-title":"Evidence for a potent antiinflammatory effect of rosiglitazone","volume":"89","author":"Mohanty","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0022","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/jc.2016-2669","article-title":"Antiinflammatory and ROS suppressive effects of the addition of fiber to a high-fat high-calorie meal","volume":"102","author":"Ghanim","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0023","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1210\/jc.2011-1508","article-title":"Exenatide exerts a potent antiinflammatory effect","volume":"97","author":"Chaudhuri","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2025.101613_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-019562","article-title":"Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial","volume":"8","author":"Antonsen","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabet.2025.101613_bib0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOL.0000000000000750","article-title":"Lipid effects of glucagon-like peptide 1 receptor analogs","volume":"32","author":"Berberich","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.diabet.2025.101613_bib0026","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.diabet.2025.101613_bib0027","unstructured":"Highlights of prescribing information, Ozempic (semaglutide) injection, for subcutaneous use. (2017). Accessed: 2024: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209637s020s021lbl.pdf."}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T23:41:28Z","timestamp":1740699688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1262363625000096"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101613","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101613"}}